NGS Kits Market - A Global and Regional Analysis: Focus on Workflow, Sequencing Type, Usage, Application, End User, and Region - Analysis and Forecast, 2022-2032
Description
NGS Kits Market - A Global and Regional Analysis: Focus on Workflow, Sequencing Type, Usage, Application, End User, and Region - Analysis and Forecast, 2022-2032
Global NGS Kits Market Industry Overview
In 2021, the global NGS kits market was valued at $4,553.6 million, and it is expected to reach $26,057.4 million by 2032, growing at a CAGR of 17.27% during the forecast period 2022-2032. The growth in the global NGS Kits market is expected to be driven by advancements in sequencing technology benefiting the treatment and diagnostics coupled with the presence of regulatory framework pertaining to sequencing and governments investing in large clinical and diagnostic laboratories to enable reliable NGS testing for a variety of chronic and infectious ailments.
Market Lifecycle Stage
The global NGS kits market is in progressing phase. Next-generation sequencing (NGS) has recently seen a rapid surge in popularity and has emerged as a crucial diagnostic tool for many diseases. The NGS kits market is a disruptive technical advancement in the life sciences sector that has cleared the way for the creation of various ground-breaking medicinal techniques intended to solve the main global health concern.
Impact
The presence of NGS kits providers of NGS kits in regions such as North America and Europe has a major impact on the market. For instance, Illumina, Inc. is one of the global leaders in providing technologically advanced sequencing and array-based solutions for genomic and genetic analysis to government laboratories, academic and research institutions, hospitals, pharmaceuticals, commercial molecular diagnostic laboratories, biotechnology, and consumer genomics companies. The company also provides sequencing solutions in the field of cancer research.
Impact of COVID-19
The COVID-19 pandemic has resulted in showcasing a positive impact on the overall market, owing to its increased adoption for the diagnosis of respiratory virus i.e. coronavirus. NGS is a useful technology for characterizing and finding viruses in the environment, animals, and people during viral pandemics. Additionally, NGS can offer helpful information to researchers and medical professionals who are trying to create the best possible treatment alternatives. Steps performed in the COVID-19 testing process include extracting RNA sample from the patients, which is then reverse transcribed to cDNA, and then amplified using PCR. Before the PCR step, however, a sample library needs to be prepared which is the most time-consuming step of the entire process. Thus, with the help of NGS kits, this protocol can be performed quickly. Therefore, with the emergence of COVID-19, the popularity of NGS kits has increased.
Market Segmentation:
Segmentation 1: by Workflow
Library Preparation
Cluster Generation
Sequencing Reagents/Kits
The global NGS Kits market in the workflow segment is expected to be dominated by the library preparation segment. This is due to an increasing number of library preparation kits and companies manufacturing these kits for their end users.
Segmentation 2: by Sequencing Type
WES and WGS
Targeted Sequencing
Long-Read Sequencing
Others
The global NGS Kits market is dominated by the WES and WGS segment owing to an increasing number of NGS kits targeting whole exome and whole genome as part of the sequencing step. Whole exome sequencing (WES) is a useful method for researchers. This kind to research might be used to continue figuring out whether new genetic variations are connected to health problems, which could help identify illnesses in the future. WGS is a technique for figuring out a person's complete DNA sequence, including non-coding DNA, which has about 3 billion nucleotides. In recent years, the cost of producing genetic data has decreased significantly. The demand for library preparation in WGS is being driven by the continuing demand for WGS in clinical and scientific applications, as well as the growing need to discover new genomic variants connected to health concerns.
Segmentation 3: by Usage
Clinical
Research
The global NGS Kits market is dominated by the research segment owing to rising number companies manufacturing research use NGS kits and rising R&D activity focused on NGS kits. There has been extensive use of NGS-detected sequence variants/mutations in research, including prognosis, therapeutic decision-making, and patient follow-up. Its extensive parallel sequencing capacity creates new opportunities for personalized therapy.
Segmentation 4: by Application
Oncology
Rare Diseases
Genetic Disorders
Reproductive Health
Others
The global NGS Kits market is dominated by the oncology segment owing to rising number companies manufacturing NGS kits for cancer. Cancer is a diverse illness that develops over time because of an accumulation of DNA abnormalities. The detection, management, and therapy of cancer would significantly impact by new sequencing technology. A road map of the typical human genome and a landscape of mutations in cancer genomes spanning many cancer types are provided by the hundreds of cancer genomes that have been read by next-generation sequencing (NGS).
Segmentation 5: by End-User
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
Clinical and Diagnostic Laboratories
Others
The academic and research institutions segment dominates the global NGS Kits market due to the increasing research and development activities in academic institutes and the focus of researchers on NGS kits.
Segmentation 6: by Region
North America - U.S., Canada
Europe – U.K., Germany, France, Italy, Spain, and Rest-of-Europe
Asia-Pacific - Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific
Latin America - Brazil, Mexico, and Rest of Latin America
Rest-of-the-World
North America generated the highest revenue of $2,281.5 million in 2021, which is attributed to the R&D advancements in the field of NGS and the presence of dominating players operating in the NGS kits market. The growth in this region can be attributed to the presence of prominent market players in the U.S. and the growing adoption of next-generation sequencing kits in research, diagnostics, and synthetic biology. In addition, the rising prevalence of infectious diseases, genetic disorders, and chronic diseases, and the development of novel library preparation kits are some of the factors that is leading to the dominance of North America in the global NGS kits market.
Recent Developments in the Global NGS Kits Market
In June 2022, PerkinElmer Inc. introduced the library preparation kits i.e. NEXTFLEX Small RNA-Seq Kit v4, NEXTFLEX Rapid XP V2 DNA-Seq Kit and PG-Seq Rapid Kit v2.
In June 2022, Beckman Coulter, Inc. partnered with Integrated DNA Technologies to distribute Biomek NGenius Next-Generation Sequencing Library Prep System. This system is a multipurpose liquid handler for NGS library preparation. The Biomek NGenius System is equipped with an FFPE DNA library prep kit and Integrated DNA Technologies' xGen cfDNA, which can help researchers optimize library generation from degraded, low-input samples such as the FFPE samples.
In March 2022, Illumina, Inc. launched the TruSight Oncology (TSO) Comprehensive (EU), a single test that detects multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. With its global launch in Europe, the IVD kit is manufactured to inform precision medicine decisions for cancer patients across the continent.
In February 2020, Thermo Fisher Scientific introduced a new NGS-based solution that enables reproductive health researchers to analyze a broad range of key genetic markers. The Ion Torrent CarrierSeq ECS Kit for the Ion GeneStudio S5 System consolidated a multi-platform approach to expanded carrier screening (ECS) into a single solution that expands the company's reproductive health research portfolio.
Demand – Drivers and Limitations
Following are the demand drivers for global NGS kits market:
Increasing Incidence of Infectious Diseases and Genetic Disorders
Exponential Rise in Next-Generation Sequencing (NGS) Demand due to Reducing Cost of Genome Sequencing
Rising Research Funding in the Genome Sciences
The market is expected to face some limitations too due to the following challenges:
Dearth of Skilled Professionals and Lack of Infrastructure in Emerging Economies
Stringent Regulatory Standards Related to NGS
How can this report add value to an organization?
Workflow/Innovation Strategy: The workflow segment helps the reader understand the two NGS steps i.e Library preparation, Cluster Generation and Sequencing. Under these steps, NGS kits are used which further aid in diagnosis. Moreover, the study provides the reader with a detailed understanding of the different applications such as oncology, NIPT, rare disease, and others.
Growth/Marketing Strategy: The NGS kits are being used for both research and clinical application. Companies are providing these kits, which is key for market players to excel in the current NGS kits market.
Competitive Strategy: Key players in the global NGS Kits market analyzed and profiled in the study have involved the NGS kits as product manufacturers Moreover, a detailed competitive benchmarking of the players operating in the global NGS Kits market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration. The leading top segment players include NGS kit manufacturers that offer major products under workflow such as library preparation, cluster generation, and sequencing in the market.
Some of the prominent names established in this market are:
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
BGI Group
Creative Biogene.
Danaher.
F. Hoffmann-La Roche Ltd
Hologic, Inc.
Illumina, Inc.
New England Biolabs
Oxford Nanopore Technologies plc.
Pacific Biosciences of California, Inc.
PerkinElmer Inc.
Promega Corporation
QIAGEN N.V.
seqWell
Takara Bio Inc.
Tecan Trading AG
Thermo Fisher Scientific, Inc.
Twist Bioscience Corporation
*PDF email from publisher allows for 1-3 users, with permission to print*
Global NGS Kits Market Industry Overview
In 2021, the global NGS kits market was valued at $4,553.6 million, and it is expected to reach $26,057.4 million by 2032, growing at a CAGR of 17.27% during the forecast period 2022-2032. The growth in the global NGS Kits market is expected to be driven by advancements in sequencing technology benefiting the treatment and diagnostics coupled with the presence of regulatory framework pertaining to sequencing and governments investing in large clinical and diagnostic laboratories to enable reliable NGS testing for a variety of chronic and infectious ailments.
Market Lifecycle Stage
The global NGS kits market is in progressing phase. Next-generation sequencing (NGS) has recently seen a rapid surge in popularity and has emerged as a crucial diagnostic tool for many diseases. The NGS kits market is a disruptive technical advancement in the life sciences sector that has cleared the way for the creation of various ground-breaking medicinal techniques intended to solve the main global health concern.
Impact
The presence of NGS kits providers of NGS kits in regions such as North America and Europe has a major impact on the market. For instance, Illumina, Inc. is one of the global leaders in providing technologically advanced sequencing and array-based solutions for genomic and genetic analysis to government laboratories, academic and research institutions, hospitals, pharmaceuticals, commercial molecular diagnostic laboratories, biotechnology, and consumer genomics companies. The company also provides sequencing solutions in the field of cancer research.
Impact of COVID-19
The COVID-19 pandemic has resulted in showcasing a positive impact on the overall market, owing to its increased adoption for the diagnosis of respiratory virus i.e. coronavirus. NGS is a useful technology for characterizing and finding viruses in the environment, animals, and people during viral pandemics. Additionally, NGS can offer helpful information to researchers and medical professionals who are trying to create the best possible treatment alternatives. Steps performed in the COVID-19 testing process include extracting RNA sample from the patients, which is then reverse transcribed to cDNA, and then amplified using PCR. Before the PCR step, however, a sample library needs to be prepared which is the most time-consuming step of the entire process. Thus, with the help of NGS kits, this protocol can be performed quickly. Therefore, with the emergence of COVID-19, the popularity of NGS kits has increased.
Market Segmentation:
Segmentation 1: by Workflow
Library Preparation
Cluster Generation
Sequencing Reagents/Kits
The global NGS Kits market in the workflow segment is expected to be dominated by the library preparation segment. This is due to an increasing number of library preparation kits and companies manufacturing these kits for their end users.
Segmentation 2: by Sequencing Type
WES and WGS
Targeted Sequencing
Long-Read Sequencing
Others
The global NGS Kits market is dominated by the WES and WGS segment owing to an increasing number of NGS kits targeting whole exome and whole genome as part of the sequencing step. Whole exome sequencing (WES) is a useful method for researchers. This kind to research might be used to continue figuring out whether new genetic variations are connected to health problems, which could help identify illnesses in the future. WGS is a technique for figuring out a person's complete DNA sequence, including non-coding DNA, which has about 3 billion nucleotides. In recent years, the cost of producing genetic data has decreased significantly. The demand for library preparation in WGS is being driven by the continuing demand for WGS in clinical and scientific applications, as well as the growing need to discover new genomic variants connected to health concerns.
Segmentation 3: by Usage
Clinical
Research
The global NGS Kits market is dominated by the research segment owing to rising number companies manufacturing research use NGS kits and rising R&D activity focused on NGS kits. There has been extensive use of NGS-detected sequence variants/mutations in research, including prognosis, therapeutic decision-making, and patient follow-up. Its extensive parallel sequencing capacity creates new opportunities for personalized therapy.
Segmentation 4: by Application
Oncology
Rare Diseases
Genetic Disorders
Reproductive Health
Others
The global NGS Kits market is dominated by the oncology segment owing to rising number companies manufacturing NGS kits for cancer. Cancer is a diverse illness that develops over time because of an accumulation of DNA abnormalities. The detection, management, and therapy of cancer would significantly impact by new sequencing technology. A road map of the typical human genome and a landscape of mutations in cancer genomes spanning many cancer types are provided by the hundreds of cancer genomes that have been read by next-generation sequencing (NGS).
Segmentation 5: by End-User
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
Clinical and Diagnostic Laboratories
Others
The academic and research institutions segment dominates the global NGS Kits market due to the increasing research and development activities in academic institutes and the focus of researchers on NGS kits.
Segmentation 6: by Region
North America - U.S., Canada
Europe – U.K., Germany, France, Italy, Spain, and Rest-of-Europe
Asia-Pacific - Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific
Latin America - Brazil, Mexico, and Rest of Latin America
Rest-of-the-World
North America generated the highest revenue of $2,281.5 million in 2021, which is attributed to the R&D advancements in the field of NGS and the presence of dominating players operating in the NGS kits market. The growth in this region can be attributed to the presence of prominent market players in the U.S. and the growing adoption of next-generation sequencing kits in research, diagnostics, and synthetic biology. In addition, the rising prevalence of infectious diseases, genetic disorders, and chronic diseases, and the development of novel library preparation kits are some of the factors that is leading to the dominance of North America in the global NGS kits market.
Recent Developments in the Global NGS Kits Market
In June 2022, PerkinElmer Inc. introduced the library preparation kits i.e. NEXTFLEX Small RNA-Seq Kit v4, NEXTFLEX Rapid XP V2 DNA-Seq Kit and PG-Seq Rapid Kit v2.
In June 2022, Beckman Coulter, Inc. partnered with Integrated DNA Technologies to distribute Biomek NGenius Next-Generation Sequencing Library Prep System. This system is a multipurpose liquid handler for NGS library preparation. The Biomek NGenius System is equipped with an FFPE DNA library prep kit and Integrated DNA Technologies' xGen cfDNA, which can help researchers optimize library generation from degraded, low-input samples such as the FFPE samples.
In March 2022, Illumina, Inc. launched the TruSight Oncology (TSO) Comprehensive (EU), a single test that detects multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. With its global launch in Europe, the IVD kit is manufactured to inform precision medicine decisions for cancer patients across the continent.
In February 2020, Thermo Fisher Scientific introduced a new NGS-based solution that enables reproductive health researchers to analyze a broad range of key genetic markers. The Ion Torrent CarrierSeq ECS Kit for the Ion GeneStudio S5 System consolidated a multi-platform approach to expanded carrier screening (ECS) into a single solution that expands the company's reproductive health research portfolio.
Demand – Drivers and Limitations
Following are the demand drivers for global NGS kits market:
Increasing Incidence of Infectious Diseases and Genetic Disorders
Exponential Rise in Next-Generation Sequencing (NGS) Demand due to Reducing Cost of Genome Sequencing
Rising Research Funding in the Genome Sciences
The market is expected to face some limitations too due to the following challenges:
Dearth of Skilled Professionals and Lack of Infrastructure in Emerging Economies
Stringent Regulatory Standards Related to NGS
How can this report add value to an organization?
Workflow/Innovation Strategy: The workflow segment helps the reader understand the two NGS steps i.e Library preparation, Cluster Generation and Sequencing. Under these steps, NGS kits are used which further aid in diagnosis. Moreover, the study provides the reader with a detailed understanding of the different applications such as oncology, NIPT, rare disease, and others.
Growth/Marketing Strategy: The NGS kits are being used for both research and clinical application. Companies are providing these kits, which is key for market players to excel in the current NGS kits market.
Competitive Strategy: Key players in the global NGS Kits market analyzed and profiled in the study have involved the NGS kits as product manufacturers Moreover, a detailed competitive benchmarking of the players operating in the global NGS Kits market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration. The leading top segment players include NGS kit manufacturers that offer major products under workflow such as library preparation, cluster generation, and sequencing in the market.
Some of the prominent names established in this market are:
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
BGI Group
Creative Biogene.
Danaher.
F. Hoffmann-La Roche Ltd
Hologic, Inc.
Illumina, Inc.
New England Biolabs
Oxford Nanopore Technologies plc.
Pacific Biosciences of California, Inc.
PerkinElmer Inc.
Promega Corporation
QIAGEN N.V.
seqWell
Takara Bio Inc.
Tecan Trading AG
Thermo Fisher Scientific, Inc.
Twist Bioscience Corporation
*PDF email from publisher allows for 1-3 users, with permission to print*
Table of Contents
253 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.1.1 Inclusion and Exclusion
- 1.1.2 Scope of Work
- 1.2 Market Overview
- 1.2.1 Introduction
- 1.2.2 Evolution of NGS Technology
- 1.2.3 Workflow of NGS Kits
- 1.2.4 Market Future Potential
- 2 Industry Insights
- 2.1 Industry Insights
- 2.1.1 Legal Requirements and Framework in the U.S.
- 2.1.2 U.S. FDA Published Guidance:
- 2.1.3 U.S. FDA Regulations
- 2.1.4 Legal Requirements and Framework in Europe
- 2.1.5 Legal Requirements and Framework in Asia-Pacific
- 2.1.5.1 China
- 2.1.5.2 Japan
- 2.1.5.2.1 Pharmaceuticals and Medical Devices Agency (PMDA)
- 2.1.5.2.2 Ministry of Health, Labour, and Welfare (MHLW)
- 2.1.5.3 India
- 2.2 Industry Trends
- 2.3 Patent Analysis
- 2.3.1 Patent Filing Trend
- 2.3.2 Patent Analysis (by Year)
- 2.3.3 Patent Analysis (by Region)
- 2.3.4 Patent Analysis (by Country)
- 3 Market Dynamics
- 3.1 Overview
- 3.1.1 Market Drivers
- 3.1.1.1 Increasing Incidence of Infectious Diseases and Genetic Disorders
- 3.1.1.2 Exponential Rise in Next-Generation Sequencing (NGS) Demand due to Reducing Cost of Genome Sequencing
- 3.1.1.3 Rising Research Funding in the Genome Sciences
- 3.1.2 Market Challenges
- 3.1.2.1 Dearth of Skilled Professionals and Lack of Infrastructure in Emerging Economies
- 3.1.2.2 Stringent Regulatory Standards Related to NGS
- 3.1.3 Market Opportunities
- 3.1.3.1 Direct-to-Consumers Service on Rise
- 3.1.3.2 Rising Application of NGS Kits in Precision Medicine and Molecular Diagnostics
- 3.1.3.3 Increase in Business and Corporate Strategy Expected to Further Strengthen the NGS Kits Market
- 3.1.4 COVID-19 Impact on Global NGS Kits Market
- 3.1.4.1 Effect of COVID-19 on R&D and Workforce
- 4 Competitive Landscape
- 4.1 Overview
- 4.1.1 Synergistic Activities
- 4.1.2 Product Launch and Product Approval
- 4.1.3 Mergers and Acquisitions
- 4.1.4 Funding Activities and Others
- 4.1.5 Market Share Analysis, 2020-2021
- 4.1.6 Growth-Share Analysis
- 4.1.6.1 Growth-Share Analysis (by Usage)
- 4.1.6.2 Growth-Share Analysis (by Application)
- 4.2 Supply Chain Analysis
- 4.2.1 Key Entities in Supply Chain
- 5 Global NGS Kits Market, by Workflow, By Value ($Million), 2021-2032
- 5.1 Overview
- 5.2 Library Preparation
- 5.2.1 Library Preparation Kits
- 5.2.2 Target Enrichment Kits
- 5.3 Cluster Generation
- 5.4 Sequencing Reagents/Kits
- 5.4.1 DNA Sequencing Kits
- 5.4.2 RNA Sequencing Kits
- 6 Global NGS Kits Market, by Sequencing Type, By Value ($Million), 2021-2032
- 6.1 Overview
- 6.2 WES and WGS
- 6.3 Targeted Sequencing
- 6.4 Long-Read Sequencing
- 6.5 Other Sequencing
- 7 Global NGS Kits Market, by Usage Area, By Value ($Million), 2021-2032
- 7.1 Overview
- 7.2 Clinical
- 7.3 Research
- 8 Global NGS Kits Market, by Application, By Value ($Million), 2021-2032
- 8.1 Overview
- 8.2 Oncology
- 8.3 Rare Diseases
- 8.4 Genetic Disorders
- 8.5 Reproductive Health
- 8.6 Others
- 9 Global NGS Kits Market, by End-User, By Value ($Million), 2021-2032
- 9.1 Overview
- 9.2 Academic and Research Institutions
- 9.3 Pharmaceutical and Biotechnology Companies
- 9.4 Clinical and Diagnostic Laboratories
- 9.5 Others
- 10 Global NGS Kits Market, by Region, $Million, 2021-2032
- 10.1 Overview
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 France
- 10.3.3 U.K.
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Rest-of-Europe
- 10.4 Asia-Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest-of-Asia-Pacific (RoAPAC)
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest-of-Latin America
- 10.6 Rest-of-the-World (RoW)
- 11 Market - Competitive Benchmarking & Company Profiles
- 11.1 Overview
- 11.2 Agilent Technologies, Inc.
- 11.2.1 Company Overview
- 11.2.2 Role of Agilent Technologies, Inc. in the Global NGS Kits Market
- 11.2.3 Key Customers of the Company
- 11.2.4 Key Competitors of the Company
- 11.2.5 Financials
- 11.2.6 Key Insights about the Financial Health of the Company
- 11.2.7 Corporate Strategies
- 11.2.8 Business Strategies
- 11.2.9 Analyst’s Perspective
- 11.3 Bio-Rad Laboratories, Inc.
- 11.3.1 Company Overview
- 11.3.2 Role of Bio-Rad Laboratories, Inc. in the Global NGS Kits Market
- 11.3.3 Key Competitors of the Company
- 11.3.4 Financials
- 11.3.5 Key Insights about the Financial Health of the Company
- 11.3.6 Corporate Strategies
- 11.3.7 Business Strategies
- 11.3.8 Analyst’s Perspective
- 11.4 BGI Group
- 11.4.1 Company Overview
- 11.4.2 Role of BGI Group in the Global NGS Kits Market
- 11.4.3 Key Competitors of the Company
- 11.4.4 Business Strategies
- 11.4.5 Analyst’s Perspective
- 11.5 Creative Biogene.
- 11.5.1 Company Overview
- 11.5.2 Role of Creative Biogene. in the Global NGS Kits Market
- 11.5.3 Key Competitors of the Company
- 11.5.4 Analyst’s Perspective
- 11.6 Danaher.
- 11.6.1 Company Overview
- 11.6.2 Role of Danaher. in the Global NGS Kits Market
- 11.6.3 Key Customers of the Company
- 11.6.4 Key Competitors of the Company
- 11.6.5 Financials
- 11.6.6 Key Insights about the Financial Health of the Company
- 11.6.7 Corporate Strategies
- 11.6.8 Business Strategies
- 11.6.9 Analyst’s Perspective
- 11.7 F. Hoffmann-La Roche Ltd
- 11.7.1 Company Overview
- 11.7.2 Role of F. Hoffmann-La Roche Ltd in the Global NGS Kits Market
- 11.7.3 Key Competitors of the Company
- 11.7.4 Corporate Strategies
- 11.7.5 Business Strategies
- 11.7.6 Financials
- 11.7.7 Key Insights about the Financial Health of the Company
- 11.7.8 Analyst’s Perspective
- 11.8 Hologic, Inc.
- 11.8.1 Company Overview
- 11.8.2 Role of Hologic, Inc. in the Global NGS Kits Market
- 11.8.3 Key Competitors of the Company
- 11.8.4 Financials
- 11.8.5 Hologic, Inc.: Revenue (by Segment), $Million, 2019-2021
- 11.8.6 Key Insights about the Financial Health of the Company
- 11.8.7 Corporate Strategies
- 11.8.8 Business Strategies
- 11.8.9 Analyst’s Perspective
- 11.9 Illumina, Inc.
- 11.9.1 Company Overview
- 11.9.2 Role of Illumina, Inc. in the Global NGS Kits Market
- 11.9.3 Key Customers of the Company
- 11.9.4 Key Competitors of the Company
- 11.9.5 Financials
- 11.9.6 Key Insights about the Financial Health of the Company
- 11.9.7 Corporate Strategies
- 11.9.8 Business Strategies
- 11.9.9 Analyst’s Perspective
- 11.1 New England Biolabs
- 11.10.1 Company Overview
- 11.10.2 Role of New England Biolabs in the Global NGS Kits Market
- 11.10.3 Key Customers of the Company
- 11.10.4 Key Competitors of the Company
- 11.10.5 Business Strategies
- 11.10.6 Analyst’s Perspective
- 11.11 Oxford Nanopore Technologies plc.
- 11.11.1 Company Overview
- 11.11.2 Role of Oxford Nanopore Technologies plc. in the Global NGS Kits Market
- 11.11.3 Key Competitors of the Company
- 11.11.4 Corporate Strategies
- 11.11.5 Business Strategies
- 11.11.6 Financials
- 11.11.7 Key Insights about the Financial Health of the Company
- 11.11.8 Analyst’s Perspective
- 11.12 Pacific Biosciences of California, Inc.
- 11.12.1 Company Overview
- 11.12.2 Role of Pacific Biosciences of California, Inc. in the Global NGS Kits Market
- 11.12.3 Key Competitors of the Company
- 11.12.4 Corporate Strategies
- 11.12.5 Financials
- 11.12.6 Key Insights about the Financial Health of the Company
- 11.12.7 Analyst’s Perspective
- 11.13 PerkinElmer Inc.
- 11.13.1 Company Overview
- 11.13.2 Role of PerkinElmer Inc. in the Global NGS Kits Market
- 11.13.3 Key Customers of the Company
- 11.13.4 Key Competitors of the Company
- 11.13.5 Business Strategies
- 11.13.6 Financials
- 11.13.7 Key Insights about the Financial Health of the Company
- 11.13.8 Analyst’s Perspective
- 11.14 Promega Corporation
- 11.14.1 Company Overview
- 11.14.2 Role of Promega Corporation in the Global NGS Kits Market
- 11.14.3 Key Customers of the Company
- 11.14.4 Key Competitors of the Company
- 11.14.5 Business Strategies
- 11.14.6 Analyst’s Perspective
- 11.15 QIAGEN N.V.
- 11.15.1 Company Overview
- 11.15.2 Role of QIAGEN N.V. in the Global NGS Kits Market
- 11.15.3 Key Customers of the Company
- 11.15.4 Key Competitors of the Company
- 11.15.5 Business Strategies
- 11.15.6 Financials
- 11.15.7 Key Insights about the Financial Health of the Company
- 11.15.8 Analyst’s Perspective
- 11.16 seqWell
- 11.16.1 Company Overview
- 11.16.2 Role of seqWell in the Global NGS Kits Market
- 11.16.3 Key Competitors of the Company
- 11.16.4 Analyst’s Perspective
- 11.17 Takara Bio Inc.
- 11.17.1 Company Overview
- 11.17.2 Role of Takara Bio Inc. in the Global NGS Kits Market
- 11.17.3 Key Customers of the Company
- 11.17.4 Key Competitors of the Company
- 11.17.5 Financials
- 11.17.6 Key Insights about the Financial Health of the Company
- 11.17.7 Analyst’s Perspective
- 11.18 Tecan Trading AG
- 11.18.1 Company Overview
- 11.18.2 Role of Tecan Trading AG in the Global NGS Kits Market
- 11.18.3 Key Customers of the Company
- 11.18.4 Key Competitors of the Company
- 11.18.5 Business Strategies
- 11.18.6 Financials
- 11.18.7 Key Insights about the Financial Health of the Company
- 11.18.8 Analyst’s Perspective
- 11.19 Thermo Fisher Scientific, Inc.
- 11.19.1 Company Overview
- 11.19.2 Role of Thermo Fisher Scientific, Inc. in the Global NGS Kits Market
- 11.19.3 Key Customers of the Company
- 11.19.4 Key Competitors of the Company
- 11.19.5 Financials
- 11.19.6 Key Insights about the Financial Health of the Company
- 11.19.1 Corporate Strategies
- 11.19.2 Business Strategies
- 11.19.3 Analyst’s Perspective
- 11.2 Twist Bioscience Corporation
- 11.20.1 Company Overview
- 11.20.2 Role of Twist Bioscience Corporation in the Global NGS Kits Market
- 11.20.3 Key Competitors of the Company
- 11.20.4 Financials
- 11.20.5 Key Insights about the Financial Health of the Company
- 11.20.6 Corporate Strategies
- 11.20.7 Business Strategies
- 11.20.8 Analyst’s Perspective
- 11.21 Emerging Companies
- 11.21.1 Paragon Genomics, Inc.
- 11.21.2 BioDynami
- 11.21.3 TransGen Biotech Co., Ltd.
- List of Figures
- Figure 1: Impact Analysis of Market Drivers, Market Challenges, and Market Opportunities on the Global NGS Kits Market
- Figure 2: Global NGS Kits Market (by Workflow), $Million, 2021 and 2032
- Figure 3: Global NGS Kits Market (by Sequencing Type), $Million, 2021 and 2032
- Figure 4: Global NGS Kits Market (by Usage), $Million, 2021 and 2032
- Figure 5: Global NGS Kits Market (by Application), $Million, 2021 and 2032
- Figure 6: Global NGS Kits Market (by End User), $Million, 2021 and 2032
- Figure 7: Global NGS Kits Market Snapshot (by Region)
- Figure 8: Global NGS Kits Market Research Methodology
- Figure 9: Global NGS Kits Market: Segmentation
- Figure 10: Development of Sequencing Techniques
- Figure 11: Workflow of NGS
- Figure 12: FDA’s Regulatory Insight System
- Figure 13: Year-Wise Analysis of Patents Related to NGS Kits, January 2019-October 2022
- Figure 14: Region-Wise Analysis of Patents Related to NGS Kits, January 2019-October 2022
- Figure 15: Country-Wise Analysis of Patents Related to NGS Kits, January 2019-October 2022
- Figure 16: Global NGS Kits Market - Market Dynamics
- Figure 17: Infectious Diseases Count in 2019 in the U.S.
- Figure 18: Advantages of Using Next-Generation Sequencing
- Figure 19: Overview of Several Important Next-Generation Sequencing Applications
- Figure 20: Key Developments: FY 2021
- Figure 21: COVID-19 Testing Workflow
- Figure 22: NGS Usage in Laboratories During the COVID-19 Pandemic
- Figure 23: Share of Key Developments and Strategies, January 2019-June 2022
- Figure 24: Share of Synergistic Activities (by Company), January 2019-June 2022
- Figure 25: Number of Product Launches (by Company), January 2019-June 2022
- Figure 26: Share of Mergers and Acquisitions (by Company), January 2019-June 2022
- Figure 27: Market Share Analysis for Global NGS Kits Market, $Million, 2020 and 2021
- Figure 28: Growth-Share Matrix for Global NGS Kits Market (by Usage), 2021
- Figure 29: Growth-Share Matrix for Global NGS Kits Market (by Application), 2021
- Figure 30: Global NGS Kits Market Supply Chain Analysis
- Figure 31: Global NGS Kits Market (by Workflow)
- Figure 32: Global NGS Kits Market (by Workflow), $Million, 2021 and 2032
- Figure 33: Global NGS Kits Market (Library Preparation), $Million, 2021-2032
- Figure 34: Global NGS Kits Market (Library Preparation Kits), $Million, 2021-2032
- Figure 35: Global NGS Kits Market (Target Enrichment Kits), $Million, 2021-2032
- Figure 36: Global NGS Kits Market (Cluster Generation), $Million, 2021-2032
- Figure 37: Sequencing Reagents/Kits: Global NGS Kits Market
- Figure 38: Global NGS Kits Market (Sequencing Reagents/Kits), $Million, 2021-2032
- Figure 39: Global NGS Kits Market (DNA Sequencing Kits), $Million, 2021-2032
- Figure 40: Global NGS Kits Market (RNA Sequencing Kits), $Million, 2021-2032
- Figure 41: Global NGS Kits Market (by Sequencing Type)
- Figure 42: Global NGS Kits Market (by Sequencing Type), $Million, 2021 and 2032
- Figure 43: Advantages: Whole-Genome Sequencing
- Figure 44: Advantages: Whole-Exome Sequencing
- Figure 45: Global NGS Kits Market (WES and WGS), $Million, 2021-2032
- Figure 46: Advantages: Targeted Sequencing
- Figure 47: Global NGS Kits Market (Targeted Sequencing), $Million, 2021-2032
- Figure 48: Global NGS Kits Market (Long-Read Sequencing), $Million, 2021-2032
- Figure 49: Global NGS Kits Market (Other Sequencing), $Million, 2021-2032
- Figure 50: Global NGS Kits Market (by Usage)
- Figure 51: Global NGS Kits Market (by Usage), $Million, 2021 and 2032
- Figure 52: Clinical Applications of NGS
- Figure 53: Global NGS Kits Market (Clinical), $Million, 2021-2032
- Figure 54: Global NGS Kits Market (Research), $Million, 2021-2032
- Figure 55: Research Applications of NGS Kits
- Figure 56: Global NGS Kits Market (by Application)
- Figure 57: Global NGS Kits Market (by Application), $Million, 2021 and 2032
- Figure 58: Clinical Oncology: Utilization of NGS
- Figure 59: Global NGS Kits Market (Oncology), $Million, 2021-2032
- Figure 60: Global NGS Kits Market (Rare Diseases), $Million, 2021-2032
- Figure 61: Global NGS Kits Market (Genetic Disorders), $Million, 2021-2032
- Figure 62: Global NGS Kits Market (Reproductive Health), $Million, 2021-2032
- Figure 63: Global NGS Kits Market (Others), $Million, 2021-2032
- Figure 64: Global NGS Kits Market (by End User)
- Figure 65: Global NGS Kits Market (by End User), $Million, 2021 and 2032
- Figure 66: Global NGS Kits Market (Academic and Research Institutions), $Million, 2021-2032
- Figure 67: Global NGS Kits Market (Pharmaceutical and Biotechnology Companies), $Million, 2021-2032
- Figure 68: Global NGS Kits Market (Clinical and Diagnostic Laboratories), $Million, 2021-2032
- Figure 69: Global NGS Kits Market (Others), $Million, 2021-2032
- Figure 70: Global NGS Kits Market Snapshot (by Region)
- Figure 71: Global NGS Kits Market (by Region), $Million, 2022-2032
- Figure 72: North America NGS Kits Market, $Million, 2022-2032
- Figure 73: North America: Market Dynamics
- Figure 74: North America NGS Kits Market (by Country), $Million, 2021-2032
- Figure 75: U.S. NGS Kits Market, $Million, 2021-2032
- Figure 76: U.S. NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 77: Canada NGS Kits Market, $Million, 2022-2032
- Figure 78: Canada NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 79: Europe NGS Kits Market, $Million, 2021-2032
- Figure 80: Europe: Market Dynamics
- Figure 81: Europe NGS Kits Market (by Country), $Million, 2021-2032
- Figure 82: Germany NGS Kits Market, $Million, 2021-2032
- Figure 83: Germany NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 84: France NGS Kits Market, $Million, 2021-2032
- Figure 85: France NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 86: U.K. NGS Kits Market, $Million, 2021-2032
- Figure 87: U.K. NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 88: Italy NGS Kits Market, $Million, 2021-2032
- Figure 89: Italy NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 90: Spain NGS Kits Market, $Million, 2021-2032
- Figure 91: Spain NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 92: Rest-of-Europe NGS Kits Market, $Million, 2021-2032
- Figure 93: Rest-of-Europe NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 94: Asia-Pacific NGS Kits Market, $Million, 2021-2032
- Figure 95: Asia-Pacific - Market Dynamics
- Figure 96: Asia-Pacific NGS Kits Market (by Country), $Million, 2021-2032
- Figure 97: China NGS Kits Market, $Million, 2021-2032
- Figure 98: China NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 99: Japan NGS Kits Market, $Million, 2021-2032
- Figure 100: Japan NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 101: India NGS Kits Market, $Million, 2021-2032
- Figure 102: India NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 103: Australia NGS Kits Market, $Million, 2021-2032
- Figure 104: Australia NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 105: South Korea NGS Kits Market, $Million, 2021-2032
- Figure 106: South Korea NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 107: Rest-of-Asia-Pacific NGS Kits Market, $Million, 2021-2032
- Figure 108: Rest-of-Asia-Pacific NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 109: Latin America NGS Kits Market, $Million, 2021-2032
- Figure 110: Latin America - Market Dynamics
- Figure 111: Latin America NGS Kits Market (by Country), $Million, 2021-2032
- Figure 112: Brazil NGS Kits Market, $Million, 2021-2032
- Figure 113: Brazil NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 114: Mexico NGS Kits Market, $Million, 2021-2032
- Figure 115: Mexico NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 116: Rest-of-Latin America NGS Kits Market, $Million, 2021-2032
- Figure 117: Rest-of-Latin America NGS Kits Market (by Usage), $Million, 2021-2032
- Figure 118: Rest-of-the-World NGS Kits Market, $Million, 2021-2032
- Figure 119: Total Number of Companies Profiled
- Figure 120: Agilent Technologies, Inc.: Product Portfolio
- Figure 121: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
- Figure 122: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 123: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 124: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 125: Bio-Rad Laboratories, Inc.: Product Portfolio
- Figure 126: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
- Figure 127: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 128: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 129: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 130: BGI Group: Product Portfolio
- Figure 131: Creative Biogene.: Product Portfolio
- Figure 132: Danaher.: Product Portfolio
- Figure 133: Danaher.: Overall Financials, $Million, 2019-2021
- Figure 134: Danaher.: Revenue (by Segment), $Million, 2019-2021
- Figure 135: Danaher.: Revenue (by Region), $Million, 2019-2021
- Figure 136: Danaher.: R&D Expenditure, $Million, 2019-2021
- Figure 137: F. Hoffmann-La Roche Ltd: Product Portfolio
- Figure 138: F. Hoffmann-La Roche Ltd: Overall Financials, 2019-2021
- Figure 139: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2019-2021
- Figure 140: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2019-2021
- Figure 141: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2019-2021
- Figure 142: Hologic, Inc.: Product Portfolio
- Figure 143: Hologic, Inc.: Overall Financials, $Million, 2019-2021
- Figure 144: Hologic, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 145: Hologic, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 146: Illumina, Inc.: Product Portfolio
- Figure 147: Illumina, Inc.: Overall Financials, $Million, 2019-2021
- Figure 148: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 149: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 150: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 151: New England Biolabs: Product Portfolio
- Figure 152: Oxford Nanopore Technologies plc.: Product Portfolio
- Figure 153: Oxford Nanopore Technologies plc.: Overall Financials, 2019-2021
- Figure 154: Oxford Nanopore Technologies plc.: Revenue (by Segment), 2019-2021
- Figure 155: Oxford Nanopore Technologies plc.: Revenue (by Region), 2019-2021
- Figure 156: Oxford Nanopore Technologies plc.: R&D Expenditure, 2019-2021
- Figure 157: Pacific Biosciences of California, Inc.: Product Portfolio
- Figure 158: Pacific Biosciences of California, Inc.: Overall Financials, 2019-2021
- Figure 159: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2019-2021
- Figure 160: Pacific Biosciences of California, Inc.: Revenue (by Region), 2019-2021
- Figure 161: Pacific Biosciences of California, Inc.: R&D Expenditure, 2019-2021
- Figure 162: PerkinElmer Inc.: Product Portfolio
- Figure 163: PerkinElmer Inc.: Overall Financials, 2019-2021
- Figure 164: PerkinElmer Inc.: Revenue (by Segment), 2019-2021
- Figure 165: PerkinElmer Inc.: Revenue (by Region), 2019-2021
- Figure 166: PerkinElmer Inc.: R&D Expenditure, 2019-2021
- Figure 167: Promega Corporation: Product Portfolio
- Figure 168: QIAGEN N.V.: Product Portfolio
- Figure 169: QIAGEN N.V.: Overall Financials, 2019-2021
- Figure 170: QIAGEN N.V.: Revenue (by Segment), 2019-2021
- Figure 171: QIAGEN N.V.: Revenue (by Region), 2019-2021
- Figure 172: QIAGEN N.V.: R&D Expenditure, 2019-2021
- Figure 173: seqWell: Product Portfolio
- Figure 174: Takara Bio Inc.: Product Portfolio
- Figure 175: Takara Bio Inc.: Overall Financials, $Million, 2019-2021
- Figure 176: Takara Bio Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 177: Takara Bio Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 178: Takara Bio Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 179: Tecan Trading AG: Product Portfolio
- Figure 180: Tecan Trading AG: Overall Financials, 2019-2021
- Figure 181: Tecan Trading AG: Revenue (by Segment), 2019-2021
- Figure 182: Tecan Trading AG: Revenue (by Region), 2019-2021
- Figure 183: Tecan Trading AG: R&D Expenditure, 2019-2021
- Figure 184: Thermo Fisher Scientific, Inc.: Product Portfolio
- Figure 185: Thermo Fisher Scientific, Inc.: Overall Financials, 2019-2021
- Figure 186: Thermo Fisher Scientific, Inc.: Revenue (by Segment), 2019-2021
- Figure 187: Thermo Fisher Scientific, Inc.: Revenue (by Region), 2019-2021
- Figure 188: Thermo Fisher Scientific, Inc.: R&D Expenditure, 2019-2021
- Figure 189: Twist Bioscience Corporation: Product Portfolio
- Figure 190: Twist Bioscience Corporation: Overall Financials, 2019-2021
- Figure 191: Twist Bioscience Corporation: Revenue (by Segment), 2019-2021
- Figure 192: Twist Bioscience Corporation: Revenue (by Region), 2019-2021
- Figure 193: Twist Bioscience Corporation: R&D Expenditure, 2019-2021
- List of Tables
- Table 1: Emerging Players in NGS Kits Market
- Table 2: List of Companies and their Library Preparation Kits
- Table 3: List of Companies and their Target Enrichment Kits
- Table 4: List of Companies and their Cluster Generation Kits
- Table 5: List of Companies and their DNA Sequencing Kits
- Table 6: Key Players of RNA Sequencing Kits
- Table 7: List of Companies and their NGS Kits
- Table 8: List of Companies and their Targeted Sequencing Kits
- Table 9: Number of NGS Tests Performed in 10 Centers during January 2019-December 2019 in Italy
- Table 10: Ongoing Genome Projects in Middle East Countries
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
